|
1) Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci. 2008; 29: 258-67
|
|
|
|
2) Timmer SA, De Boer K, Knaapen P, et al. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis？ J Card Fail. 2009; 15: 353-61
|
|
|
|
|
|
3) Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure？ J Am Coll Cardiol. 2009; 53: 639-47
|
|
|
|
|
|
4) Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008; 13: 387-92
|
|
|
|
|
|
5) Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003; 112: 999-1007
|
|
|
|
|
|
6) Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003; 100: 4802-6
|
|
|
|
|
|
7) Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004; 18: 1031-3
|
|
|
|
|
|
8) Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006; 48: 176-84
|
|
|
|
|
|
9) Ueda K, Takano H, Niitsuma Y, et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest. 2010; 120: 2016-29
|
|
|
|
|
|
10) Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002; 100: 2279-88
|
|
|
|
|
|
11) Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004; 103: 921-6
|
|
|
|
|
|
12) Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angio-poietin-2, modulate VEGF-induced postnatal neo-vascularization. Circ Res. 1998; 83: 233-40
|
|
|
|
|
|
13) Wang L, Zhang ZG, Gregg SR, et al. The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem. 2007; 282: 32462-70
|
|
|
|
|
|
14) Washington Smoak I, Byrd NA, Abu-Issa R, et al. Sonic hedgehog is required for cardiac outflow tract and neural crest cell development. Dev Biol. 2005; 283: 357-72
|
|
|
|
|
|
15) Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med. 2001; 7: 706-11
|
|
|
|
|
|
16) Kusano KF, Pola R, Murayama T, et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med. 2005; 11: 1197-204
|
|
|
|
|
|
17) Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med. 2005; 11: 305-11
|
|
|
|
|
|
18) Takano H, Ueda K, Hasegawa H, et al. G-CSF therapy for acute myocardial infarction. Trends Pharmacol Sci. 2007; 28: 512-7
|
|
|
|
|
|
19) Lipsic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006; 20: 135-41
|
|
|
|
|
|
20) Liem A, van de Woestijne AP, Bruijns E, et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol. 2009; 131: 285-7
|
|
|
|
|
|
21) Binbrek AS, Rao NS, Al Khaja N, et al. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol. 2009; 104: 1035-40
|
|
|
|
|
|
22) Ozawa T, Toba K, Suzuki H, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -. Circ J. 2010; 74: 1415-23
|
|
|
|
|
23) Tang YD, Hasan F, Giordano FJ, et al. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. Am Heart J. 2009; 158: 941-7
|
|
|
|
|
|
24) Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 45: 1406-12
|
|
|
|
|